Yamamoto Yoshiaki, Matsuyama Hideyasu, Kawauchi Shigeto, Furuya Tomoko, Liu Xiu Ping, Ikemoto Kenzo, Oga Atsunori, Naito Katsusuke, Sasaki Kohsuke
Department of Urology, Yamaguchi University School of Medicine, Ube, Yamaguchi, Japan.
Clin Cancer Res. 2006 May 1;12(9):2752-8. doi: 10.1158/1078-0432.CCR-05-0805.
Malignant tumors show an inherent genetic instability that can be classified as microsatellite instability (MSI) or chromosomal instability (CIN). To elucidate the differences in biological characteristics of bladder cancer between the two types of genetic instability, the expression of the mismatch repair (MMR) proteins, Aurora-A and p53 proteins, the number of centrosomes, numerical aberrations of chromosomes and 20q13, and DNA ploidy were examined in 100 human urothelial carcinomas of the bladder.
Expressions of the MLH1, MSH2, Aurora-A, and p53 proteins and the numbers of centrosomes were immunohistochemically assessed. Numerical aberrations of chromosomes 7, 9, 17, and 20q13 spots were evaluated by fluorescence in situ hybridization, and DNA ploidy was assessed by laser scanning cytometry.
The expression levels of the MMR related-proteins decreased in 9 of 100 tumors. Tumors with low MLH1 or MSH2 expression (designated as MSI cancers) were not linked with centrosome amplification, Aurora-A overexpression, increased p53 immunoreactivity, 20q13 gain, DNA aneuploidy, and disease progression. MSI cancers showed a favorable prognosis. CIN cancers (49 cases), defined as tumors with a large intercellular variation in centromere copy numbers, were associated more frequently with centrosome amplification, Aurora-A overexpression, increased p53 immunoreactivity, and 20q13 gain than the others (51 cases). Tumors with disease progression were included in the CIN cancer group.
The present observations suggest that there are differences in the biological characteristics of the two types of genetic instability.
恶性肿瘤表现出内在的基因不稳定性,可分为微卫星不稳定性(MSI)或染色体不稳定性(CIN)。为阐明这两种基因不稳定性类型的膀胱癌生物学特性差异,在100例人膀胱尿路上皮癌中检测错配修复(MMR)蛋白、极光激酶A(Aurora-A)和p53蛋白的表达、中心体数量、染色体及20q13的数目畸变以及DNA倍体情况。
采用免疫组织化学方法评估MLH1、MSH2、Aurora-A和p53蛋白的表达以及中心体数量。通过荧光原位杂交评估染色体7、9、17和20q13位点的数目畸变,采用激光扫描细胞术评估DNA倍体。
100例肿瘤中有9例MMR相关蛋白表达水平降低。MLH1或MSH2低表达的肿瘤(称为MSI癌症)与中心体扩增、Aurora-A过表达、p53免疫反应性增加、20q13获得、DNA非整倍体及疾病进展无关。MSI癌症预后良好。CIN癌症(49例)定义为着丝粒拷贝数细胞间变异大的肿瘤,与其他肿瘤(51例)相比,更常与中心体扩增、Aurora-A过表达、p53免疫反应性增加及20q13获得相关。疾病进展的肿瘤纳入CIN癌症组。
目前的观察结果表明,这两种基因不稳定性类型的生物学特性存在差异。